A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

Gary Onik MD27 enrolled

Overview

A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Adenocarcinoma

Interventions

Immunotherapeutic AgentsDRUG

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

AblationDEVICE

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment with the MyVaccx System * Greater than 18 years of age * Signature of the informed consent Exclusion Criteria: * 2 subjects treated with the MyVaccx System with known visceral disease

Locations (1)

The Center for High Risk and Recurrent Prostate Cancer

Fort Lauderdale, Florida, United States

Outcomes

Primary Outcomes

MyVaccx immunotherapy treatment impact on late stage cancer disease

Time to death after the start of treatment

Time frame: From date of treatment until the date of death from any cause up to 60 months

Secondary Outcomes

MyVaccx immunotherapy treatment impact on late stage cancer disease

Complete and partial response to treatment based on the iRESIST criteria

Time frame: Time to progression after a complete or partial response up to 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.